scispace - formally typeset
P

Phillip P. Sharp

Researcher at University of California, San Francisco

Publications -  25
Citations -  4838

Phillip P. Sharp is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Bromodomain & BRD4. The author has an hindex of 15, co-authored 23 publications receiving 3236 citations. Previous affiliations of Phillip P. Sharp include University of Melbourne & Walter and Eliza Hall Institute of Medical Research.

Papers
More filters
Journal ArticleDOI

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.

David E. Gordon, +128 more
- 30 Apr 2020 - 
TL;DR: A human–SARS-CoV-2 protein interaction map highlights cellular processes that are hijacked by the virus and that can be targeted by existing drugs, including inhibitors of mRNA translation and predicted regulators of the sigma receptors.
Posted ContentDOI

A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing

David E. Gordon, +123 more
- 22 Mar 2020 - 
TL;DR: The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains.
Journal ArticleDOI

CIS is a potent checkpoint in NK cell–mediated tumor immunity

TL;DR: This work has identified cytokine-inducible SH2-containing protein (CIS, encoded by Cish) as a critical negative regulator of IL-15 signaling in NK cells, and uncovered a potent intracellular checkpoint in NK cell–mediated tumor immunity.
Journal ArticleDOI

BET bromodomain inhibitors: a patent review

TL;DR: There is now compelling preclinical data demonstrating BET inhibition as a strategy to target processes known to be involved in disease development and progression with clinical trials of two bona fide BET inhibitors now underway.